ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021
ADC Therapeutics (NYSE: ADCT) has announced a conference call on May 6, 2021, at 8:30 a.m. EDT to discuss its first quarter financial results and business updates. The call can be accessed via phone or through a live webcast on the company’s investor website. ADC Therapeutics is focused on developing antibody drug conjugates (ADCs) aimed at treating various cancers, including its FDA-approved ADC ZYNLONTA for lymphoma. The company also has ongoing clinical trials for other ADCs targeting hematological malignancies and solid tumors.
- FDA-approved ADC ZYNLONTA for treating lymphoma.
- Ongoing late-stage clinical trials for ZYNLONTA and Cami.
- None.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, May 6, 2021 at 8:30 a.m. EDT to report financial results for the first quarter 2021 and provide business updates.
To access the live call, please dial 888-771-4371 (domestic) or +1 847-585-4405 (international) and provide confirmation number 50158735. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA™ (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA™ is a trademark of ADC Therapeutics SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005324/en/
FAQ
When will ADC Therapeutics report its first quarter 2021 financial results?
What is ZYNLONTA and its approval status?
How can I access the ADC Therapeutics conference call?
Where can I find the live webcast for the ADC Therapeutics conference call?
